文献速递神经肿瘤

1型和2型神经纤维瘤病相关肿瘤中程序性死亡配体1的表达与肿瘤浸润淋巴细胞

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
PubMed 文献 · J Neurooncol · 2018-02-09

研究对1型神经纤维瘤病(NF1)相关的10例皮肤神经纤维瘤和6例丛状神经纤维瘤,以及2型神经纤维瘤病(NF2)相关的10例脑膜瘤和10例神经鞘瘤进行免疫组化检测PD-L1(克隆SP142和E1L3N)、CD3、CD20、CD8和CD68。以肿瘤细胞膜染色>5%为PD-L1阳性,丛状神经纤维瘤(6/6和5/6)、皮肤神经纤维瘤(8/10和6/10)、神经鞘瘤(7/10和10/10)、脑膜瘤(4/10和2/10)呈PD-L1阳性。36例(100%)肿瘤标本中可见稀疏至中等量的CD68、CD3或CD8阳性肿瘤浸润淋巴细胞(TILs)。

要点

  • NF1相关丛状神经纤维瘤和皮肤神经纤维瘤中PD-L1表达阳性率较高。
  • NF2相关神经鞘瘤和脑膜瘤中PD-L1表达阳性率分别为7/10和10/10(SP142和E1L3N克隆)及4/10和2/10。
  • 全部36例肿瘤标本中均可见稀疏至中等量的CD68、CD3或CD8阳性TILs。

核心结论

  • 研究结果表明,对细胞介导免疫的适应性抵抗可能在NF1和NF2相关肿瘤的免疫微环境中起主要作用。
  • 肿瘤细胞表达PD-L1及存在TILs提示这些肿瘤可能对免疫检查点抑制剂治疗有反应,应在NF患者的临床试验中探索。

研究设计与样本

  • 采用档案库中福尔马林固定石蜡包埋组织,对NF1相关肿瘤(10例皮肤神经纤维瘤和6例丛状神经纤维瘤)及NF2相关肿瘤(10例脑膜瘤和10例神经鞘瘤)进行PD-L1(克隆SP142和E1L3N)、CD3、CD20、CD8和CD68免疫组化检测。

主要发现

  • PD-L1在肿瘤细胞中的表达(分别使用SP142和E1L3N克隆)在丛状神经纤维瘤中阳性为6/6和5/6,皮肤神经纤维瘤为8/10和6/10,神经鞘瘤为7/10和10/10,脑膜瘤为4/10和2/10。
  • 以肿瘤细胞膜染色>5%为PD-L1阳性判定标准,参照既往发表的生物标志物研究。
  • 36例(100%)肿瘤标本中可见稀疏至中等量的CD68、CD3或CD8阳性TILs。

关键数值与推荐

  • PD-L1阳性判定标准为肿瘤细胞膜染色>5%,参照既往发表的生物标志物研究。

临床怎么用

  • 作者认为,肿瘤细胞表达PD-L1及存在TILs提示这些肿瘤可能对免疫检查点抑制剂治疗有反应,应在NF患者的临床试验中探索。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) have been shown to be effective in treating patients with a variety of cancers. Biomarker studies have found positive associations between clinical response rates and PD-L1 expression on tumor cells, as well as the presence of tumor infiltrating lymphocytes (TILs). It is currently unknown whether tumors associated with neurofibromatosis types 1 and 2 (NF1 and NF2) express PD-L1. We performed immunohistochemistry for PD-L1 (clones SP142 and E1L3N), CD3, CD20, CD8, and CD68 in NF1-related tumors (ten dermal and six plexiform neurofibromas) and NF2-related tumors (ten meningiomas and ten schwannomas) using archival formalin-fixed paraffin-embedded tissues. Expression of PD-L1 was considered positive in cases with > 5% membranous staining of tumor cells, in accordance with previously published biomarker studies. PD-L1 expression in tumor cells (using the SP142 and E1L3N clones, respectively) was assessed as positive in plexiform neurofibromas (6/6 and 5/6) dermal neurofibromas (8/10 and 6/10), schwannomas (7/10 and 10/10), and meningiomas (4/10 and 2/10). Sparse to moderate presence of CD68, CD3, or CD8 positive TILs was found in 36 (100%) of tumor specimens. Our findings indicate that adaptive resistance to cell-mediated immunity may play a major role in the tumor immune microenvironment of NF1 and NF2-associated tumors. Expression of PD-L1 on tumor cells and the presence of TILs suggest that these tumors might be responsive to immunotherapy with immune checkpoint inhibitors, which should be explored in clinical trials for NF patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wang S, Liechty B, Patel S, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018. PMID: 29427150. doi:10.1007/s11060-018-2788-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。